Journals / Ege Tıp Dergisi / 2019 / Cilt: 58 - Sayı: 3

Evaluation of risk factors associated with fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae urinary tract infections

Üriner sistem enfeksiyonlarından izole edilen Escherichia coli ve Klebsiella pneumoniae suşlarında florokinolon direncini etkileyen risk faktörlerinin değerlendirilmesi

Pages
215–221
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Identification of preventable factors leading to antibiotic resistance and taking the necessary precautions are important both in empirical antibiotherapy selection and in decreasing resistance rates together with rational antibiotic use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The increased antimicrobial resistance rates limit oral empirical treatment options in urinary tract infections.
📊
Key Findings & Data:Materials and Methods: A total of 76 patients who were admitted to the outpatient urology clinic were analyzed retrospectively from January 2015 through December 2017.
💡
Conclusion & Impact:Conclusion: Identification of preventable factors leading to antibiotic resistance and taking the necessary precautions are important both in empirical antibiotherapy selection and in decreasing resistance rates together with rational antibiotic use.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: The increased antimicrobial resistance rates limit oral empirical treatment options in urinary tract infections. Determining risk factors associated with antibiotic resistance is important in terms of empirical antibiotic selection. We aimed to evaluate fluoroquinolone resistance and risk factors in Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) strains isolated from urine cultures. Materials and Methods: A total of 76 patients who were admitted to the outpatient urology clinic were analyzed retrospectively from January 2015 through December 2017. Possible risk factors associated with fluoroquinolone resistance were analyzed statistically. Results: Sixty (78.9%) of the patients were female and 16 (21.1%) were male and mean age was 54.1 ± 19.6 years. The fluoroquinolone resistance was 55.3% and extended spectrum beta-lactamase positivity rates were 15.8%. Complicated urinary tract infection (p=0.009), urolithiasis (p=0.014), uropathology (p=0.002), urological intervention (p=0.040) and prior antibiotic use (p<0.001) were significantly associated with fluoroquinolone resistance. The weak positive correlation was found between complicated urinary tract infection, urolithiasis, uropathology, urological intervention and fluoroquinolone resistance and prior antibiotic use was showed moderately positive correlation with fluoroquinolone resistance (p<0.05). Prior antibiotic use is identified as an independent risk factor for fluoroquinolone resistance (p=0.005). Conclusion: Identification of preventable factors leading to antibiotic resistance and taking the necessary precautions are important both in empirical antibiotherapy selection and in decreasing resistance rates together with rational antibiotic use.

Özet

Amaç: Antimikrobiyal direnç oranlarındaki artış, üriner sistem enfeksiyonlarında oral ampirik tedavi seçeneklerini kısıtlamaktadır. Dirençle ilgili risk faktörlerini belirlemek, ampirik antibiyotik seçimine yol göstermesi açısından önemlidir. Çalışmamızda, polikliniğe ayaktan başvuran hastaların idrar kültürlerinden izole edilen Escherichia coli (E. coli) ve Klebsiella pneumoniae (K. pneumoniae) suşlarında florokinolon direnci ve risk faktörlerini değerlendirmeyi amaçladık. Gereç ve Yöntem: Ocak 2015-Aralık 2017 tarihleri arasında üroloji polikliniğine başvuran ve idrar kültüründe E. coli ve K. pneumoniae üremesi olan 76 hastanın demografik verileri geriye dönük olarak değerlendirildi. Florokinolon direncine etki edebilecek olası risk faktörleri istatistiksel olarak incelendi. Bulgular: Hastaların 60 (%78.9)’ ı kadın ve 16 (% 21.1)’ i erkekti ve yaş ortalaması 54.1 ± 19.6 yıl olarak bulundu. Florokinolon direnci %55.3, genişlemiş spektrumlu beta-laktamaz pozitifliği %15.8 olarak saptandı. Florokinolon direnci açısından komplike idrar yolu enfeksiyonu (p = 0.009), üriner sistem taşı (p = 0.014), üropatoloji (p = 0.002), ürolojik girişim öyküsü (p = 0.040) ve önceden antibiyotik kullanım öyküsü (p<0.001) anlamlı bulundu. Üriner sistem taşı, üropatoloji, ürolojik girişim öyküsü ve komplike idrar yolu enfeksiyonu varlığı ile florokinolon direnci arasında zayıf derecede pozitif yönde; önceden antibiyotik kullanım öyküsü ile florokinolon direnci arasında ise orta derecede pozitif yönde ve istatistiksel olarak anlamlı korelasyon bulundu (p<0.05). Son 6 ay içinde antibiyotik kullanımı öyküsü, florokinolon direnci açısından bağımsız risk faktörü olarak bulundu (p=0.005). Sonuç: Antibiyotik direncine neden olan önlenebilir faktörlerin belirlenerek gerekli önlemlerin alınması, hem ampirik antibiyoterapi seçiminde yol gösterici olması hem de akılcı antibiyotik kullanımı ile birlikte direnç oranlarını azaltabilmek açısından önemlidir.

🔖

Cite This Article

ŞEN, P., İRER, B., DEMİRDAL, T., YAYGIN, Y. E. (2019). Evaluation of risk factors associated with fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae urinary tract infections. Ege Tıp Dergisi, Cilt: 58 - Sayı: 3, 215–221. https://ajindex.com/articles/164483

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Tekin A, Deveci Ö, Dal T, Tekin R, Özekinci T, Dayan S. Üropatojen Escherichia coli izolatlarına fosfomisin ve bazı antibiyotiklerin in vitro etkinliği. Ankem Derg 2012; 26 (2): 61-68
  2. Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community- and hospitalacquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC Infect Dis. 2015; 15: 545
  3. Soydan S, Karadağ G, Çalışkan E, Kale E. In vitro susceptibility analysis of Escherichia coli strains isolated from urinary tract infections to fosfomycin, nitrofurantoin and ciprofloxacin. Mediterr J Infect Microb Antimicrob. 2015; 4: 3
  4. Aykan ŞB, Çiftçi İH. Türkiye’de İdrar Kültürlerinden İzole Edilen Escherichia coli Suşlarının Antibiyotiklere Direnç Durumu: Bir Meta-Analiz. Mikrobiyol Bul 2013; 47 (4): 603-618
  5. Gupta K, Hooton TM, Naber KG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guideline for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52 (5): e103–120
  6. Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis 2012;2012:976273
  7. Shah A, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Application of Fluoroquinolone Resistance Score in Management of Complicated Urinary Tract Infections. Antimicrob Agents Chemother. 2017; 61 (5). pii: e02313-16
  8. The European Committee on Antimicrobial Susceptibility Testing. Ref: Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. http://www.eucast.org (15/04/2018)
  9. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18 (4): 657-686
  10. Kratochwill L, Powers M, McGraw MA, King L, O'Neill JM, Venkat A. Factors associated with ciprofloxacin resistant Escherichia coli urinary tract infections in discharged ED patients. Am J Emerg Med. 2015; 33 (10): 1473-1476. 11. de Lastours V, Fantin B. Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. Future Microbiol. 2015; 10 (7): 1241-1255
  11. World Health Organisation. Antimicrobial resistance: global report on surveillance. 2014. http://www.who.int/drugre